The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease

The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease European Journal of Clinical Pharmacology (2018) 74:1361–1362 https://doi.org/10.1007/s00228-018-2492-7 LETTER TO THE EDITOR The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease 1 2 3 4 1,4 4 David Pineles & Lisa Malter & Peter S. Liang & Amy Arsuaga & Brian Bosworth & David P. Hudesman & Shannon Chang Received: 29 April 2018 / Accepted: 22 May 2018 / Published online: 31 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 We read with great interest a recent paper by Boone et al. [1]. penetration into our marketplace has only recently accelerated. In this 1-year observational study, the authors sought to quan- As such, we recently performed a small, prospective study tify the nocebo rate in individuals with an immune-mediated aimed at gauging IBD patients’ initial perceptions of inflammatory disease who were switched from the originator biosimilars. In 2017, we surveyed 132 adult patients with infliximab to a biosimilar for a non-medical reason. Patients IBD at two university-affiliated gastroenterology clinics regard- were provided informed consent and voluntarily agreed to ing their current impression of biosimilars. A standardized cov- transition to the infliximab biosimilar. The patients in this er sheet was included with the 14-question survey http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease

Loading next page...
 
/lp/springer_journal/the-nocebo-effect-and-patient-perceptions-of-biosimilars-in-pB1W3KZBIn
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
D.O.I.
10.1007/s00228-018-2492-7
Publisher site
See Article on Publisher Site

Abstract

European Journal of Clinical Pharmacology (2018) 74:1361–1362 https://doi.org/10.1007/s00228-018-2492-7 LETTER TO THE EDITOR The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease 1 2 3 4 1,4 4 David Pineles & Lisa Malter & Peter S. Liang & Amy Arsuaga & Brian Bosworth & David P. Hudesman & Shannon Chang Received: 29 April 2018 / Accepted: 22 May 2018 / Published online: 31 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 We read with great interest a recent paper by Boone et al. [1]. penetration into our marketplace has only recently accelerated. In this 1-year observational study, the authors sought to quan- As such, we recently performed a small, prospective study tify the nocebo rate in individuals with an immune-mediated aimed at gauging IBD patients’ initial perceptions of inflammatory disease who were switched from the originator biosimilars. In 2017, we surveyed 132 adult patients with infliximab to a biosimilar for a non-medical reason. Patients IBD at two university-affiliated gastroenterology clinics regard- were provided informed consent and voluntarily agreed to ing their current impression of biosimilars. A standardized cov- transition to the infliximab biosimilar. The patients in this er sheet was included with the 14-question survey

Journal

European Journal of Clinical PharmacologySpringer Journals

Published: May 31, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off